325P Net treatment benefit (NTB) from either endocrine therapy plus palbociclib (ET/P) or capecitabine (C) in GEICAM/2013-02_PEARL, a phase III trial in hormone receptor-positive, HER2-negative metastatic breast cancer
B. Bermejo(Hospital Clínico Universitario de Valencia), S. Salvaggio(North Atlantic Treaty Organization), José Á. García-Sáenz(Hospital Clínico San Carlos), Oriana Ciani(Bocconi University), E.D. Saad(International Drug Development Institute (Belgium)), Eduardo Carrasco(GEICAM – Spanish Breast Cancer Group), Jean‐Christophe Chiêm(Novadip (Belgium)), María Isabel Casas(GEICAM – Spanish Breast Cancer Group), M.J. Gil(Institut Català d'Oncologia), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), E.M. Ciruelos(Hospital Universitario 12 De Octubre), Montserrat Muñoz-Mateu(Hospital Clínic de Barcelona), Mireia Margelí Vila(Institut Català d'Oncologia), A. Antón Torres(Hospital Universitario Miguel Servet), Zsuzsanna Kahán(University of Szeged), Tibor Csőszi(BM Központi Kórház), Eric Gauthier(Pfizer (United States)), C. Zielinski(Universitätszahnklinik Wien), M.E. Buyse(Clinique Saint Pierre), M. Martín Jiménez(Hospital General Universitario Gregorio Marañón)
Cited by 0Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis